Given that either pre‐ischaemic or post‐I/R FGF2 treatment delivers similar potency of protection, our work suggests that FGF2 has the potential to be used for the prevention as well as treatment of I/RI‐related AKI. This evidence concerns the gene FGF2 and acute kidney injury.